← MyLongPath

Baricitinib

MedicationExperimental3 reviews
+3.7
Average score out of 5
Based on 3 experience(s)
Experimental — This treatment is under research. Available data is limited. Consult your doctor before making any decision.

Baricitinib is an immunomodulatory drug that inhibits Janus kinase (JAK) enzymes to reduce inflammation. It is being investigated in Long COVID to treat persistent systemic inflammation.

Information
Subcategory
Janus kinase (JAK) inhibitor
Evidence level
2/5
Evidence type
ongoing clinical trials (RECOVER-TLC program)
Score distribution
+5
1 (33%)
+3
2 (67%)
+1
0 (0%)
0
0 (0%)
Negative
0 (0%)
Most improved symptoms
Post-exertional malaise
100%
Chronic fatigue
100%
Brain fog
100%
Muscle weakness
67%
Practical information
Time to effect
< 1 week
Reported side effects
None. No immunosuppression (33%)
Latest reviews
F
Anonymous review+5
65+ · 4/21/2026
F
Anonymous review+3
65+ · 4/21/2026
F
Anonymous review+3
65+ · 4/21/2026
Share your experience

Your feedback helps thousands of people find what really works.

Join the community